ATP7B Reference Standards for Multi-Platform Wilson Disease Assay Validation

For laboratories developing and validating genetic tests for Wilson disease (WD), selecting appropriate ATP7B reference standards is an important part of establishing a controlled and reproducible assay. Wilson disease testing may use Sanger sequencing, quantitative real-time PCR (qPCR), droplet digital PCR (ddPCR), or targeted next-generation sequencing (NGS). Each workflow requires well-characterized genomic DNA reference materials to evaluate analytical performance, monitor run-to-run consistency, and support reliable ATP7B variant detection and genotyping.

Suitable ATP7B reference standards should have clearly defined genotypes and variant identities, a relevant sample matrix, compatibility with the intended method, and characteristics aligned with the laboratory's validation plan. This article reviews the principal considerations when selecting ATP7B reference standards for multi-platform Wilson disease assay validation.

I. The Role of ATP7B Reference Standards in Assay Validation

A theoretical assay design alone is not sufficient to validate an ATP7B test for Wilson disease. Laboratories need well-characterized reference materials to challenge the complete workflow and assess the consistency and accuracy of genotype calls. ATP7B reference standards can help address practical questions during assay development and routine testing:

1. Can the assay distinguish wild-type, heterozygous, and homozygous ATP7B genotypes?

2. Are variant allele frequency (VAF) measurements reproducible across analytical runs?

3. Does workflow performance remain consistent when the operator changes?

4. Can the amplification or sequencing platform consistently detect the ATP7B c.2333G>T (p.R778L) variant reported in East Asian populations?

5. Can the bioinformatics pipeline distinguish a true disease-causing variant from sequencing background noise?

6. Does the workflow, including nucleic acid extraction, library preparation, and amplification where applicable, adequately represent the intended peripheral blood-derived genomic DNA workflow?

Without standardized ATP7B reference standards, it can be difficult to determine whether an unexpected genotype result arises from the sample, primer or probe design, instrument performance, reagent lot variation, or the data-analysis pipeline.

II. Key Criteria for Selecting ATP7B Reference Standards

When selecting ATP7B reference materials for Wilson disease testing, laboratories should evaluate the following characteristics:

2.1 The genotype has been double-verified to cover the core hotspot variations in the East Asian population.

A primary requirement is a clearly defined genotype for a clinically relevant variant, characterized by appropriate methods. A Wilson disease assay validation set should include three core genotype categories:

· ATP7B wild-type reference material: a negative control with no c.2333G>T variant

· ATP7B c.2333G>T heterozygous variant reference material: a positive control representing a heterozygous carrier genotype

· ATP7B c.2333G>T homozygous variant reference material: a positive control representing a homozygous affected genotype

The ATP7B c.2333G>T (p.Arg778Leu; p.R778L; rs28942074) variant is frequently reported among patients with Wilson disease in East Asian populations. A wild-type reference material can be used to assess analytical specificity and false-positive signals, while heterozygous and homozygous variant materials can be used to assess genotype detection and discrimination. Variant-positive materials alone do not provide a complete validation set; a wild-type control is also needed to evaluate assay behavior in a negative genomic background.

2.2 Human Genomic DNA Matrix Relevant to Clinical Testing

Wilson disease genetic testing commonly uses genomic DNA extracted from peripheral blood. An ATP7B reference material based on human genomic DNA provides a whole-genome background and DNA characteristics that are more representative of clinical testing samples than plasmids or short synthetic fragments. The extent to which it represents extraction-related matrix effects depends on the supplied material format and its intended use.

· PCR-based assays: human genomic DNA provides a whole-genome background for evaluating primer specificity and allele-specific amplification bias at the ATP7B locus.

· NGS assays: genomic DNA can be carried through fragmentation, library preparation, and target-enrichment steps to evaluate workflow performance. Its suitability for validating nucleic acid extraction depends on whether the material is supplied in a matrix that enters the workflow before extraction.

For validation studies intended to reflect clinical testing conditions, matched human genomic DNA reference materials may provide more relevant information than synthetic templates containing only a single variant.

2.3 Use in PCR and Digital PCR Workflows

Sanger sequencing, qPCR, and digital PCR are commonly used to detect or quantify ATP7B variants through targeted amplification of relevant exons. ATP7B reference standards designed for PCR- and ddPCR-based workflows can support the following studies:

· Analytical specificity of primer and probe sets targeting an ATP7B variant

· Calibration or evaluation of absolute VAF quantification by ddPCR

· Assessment of wild-type background signals and the false-positive rate

· Evaluation of inter-run reproducibility of amplification results

· Operator training and routine use as positive and negative assay controls

2.4 Use in Targeted NGS Panel Validation

Targeted NGS panels are used for Wilson disease carrier screening and ATP7B variant analysis, including detection of the c.2333G>T variant and other pathogenic or likely pathogenic variants within the regions covered by the panel. ATP7B genotype calls in an NGS workflow may be affected by panel design, sequencing depth, coverage uniformity, DNA input, library-preparation bias, variant-calling algorithms, and bioinformatics filtering thresholds. ATP7B reference standards can support validation across the NGS workflow:

· Evaluation of target-enrichment performance across ATP7B exons included in the panel

· Assessment of sequencing depth and coverage uniformity

· Optimization of thresholds for heterozygous variant calling

· Cross-platform comparison of PCR- and NGS-based results

· Ongoing quality control monitoring of the sequencing workflow, where supported by the material's stability and intended-use documentation

2.5 A Multi-Genotype Set for Broader Validation

A complete ATP7B reference standard set should not be limited to a single wild-type or variant-positive sample. A combination of wild-type, heterozygous, and homozygous variant materials represents three genotype categories relevant to unaffected individuals, heterozygous carriers, and individuals with a homozygous genotype. The set can be used to assess assay behavior across different genetic backgrounds and to construct a more complete validation study.

III. CB-Gene ATP7B Reference Standards: A Multi-Genotype Genomic DNA Set for Wilson Disease Assay Validation

CB-Gene has developed ATP7B molecular diagnostic reference standards for multi-platform Wilson disease assay development and validation. The CB-Gene ATP7B reference standard set contains three human genomic DNA materials representing the principal genotypes for the ATP7B c.2333G>T (p.R778L) variant:

 

The genotypes in the CB-Gene ATP7B reference standard set are characterized using Sanger sequencing, a widely used orthogonal method for variant confirmation, and digital PCR. The materials are designed for use in selected PCR-, ddPCR-, and targeted NGS-based Wilson disease assay development and validation workflows.

IV. How CB-Gene ATP7B Reference Standards Support PCR/ddPCR Validation

For amplification-based workflows, CB-Gene ATP7B reference standards focus on the ATP7B c.2333G>T variant and can be used in PCR/ddPCR performance studies that include:

1. Evaluation of specific amplification at the ATP7B target exon

2. Assessment of ddPCR accuracy for absolute VAF quantification

3. Genotype discrimination among wild-type, heterozygous, and homozygous materials

4. Evaluation of inter-run reproducibility and instrument performance

5. Assessment and minimization of false-positive variant signals in a wild-type genomic background

Because the set includes a wild-type material and two variant-positive materials, it can provide a more balanced validation dataset than a single control material.

V. How CB-Gene ATP7B Reference Standards Support Targeted NGS Panel Validation

For sequencing workflows, CB-Gene’s ATP7B reference standards can support evaluation of both wet-laboratory processes and bioinformatics analysis:

Wet-Laboratory Evaluation

The genomic DNA materials can be introduced at the appropriate stage of the workflow to evaluate DNA input tolerance, library-preparation efficiency, and coverage uniformity across the targeted ATP7B region. Validation of the extraction step requires a material supplied in a suitable pre-extraction matrix.

Bioinformatics Evaluation

The materials can be used to evaluate whether variant-calling algorithms and filtering thresholds correctly identify heterozygous and homozygous c.2333G>T genotypes and to assess false-negative and false-positive results.

The reference standards can support the following NGS validation scenarios:

1. Evaluation of target-enrichment performance for an ATP7B targeted gene panel

2. Optimization of heterozygous variant-calling thresholds

3. Assessment of cross-platform concordance among Sanger sequencing, ddPCR, and NGS results

4. Ongoing quality control monitoring of the sequencing workflow, where supported by the material's stability data and intended use

For laboratories developing multigene hereditary disease panels that include ATP7B, reference materials characterized by Sanger sequencing and ddPCR can provide orthogonal evidence for evaluating genotype calls.

VI. A Structured Validation Plan Using ATP7B Reference Standards

A Wilson disease ATP7B assay validation study may use the following stepwise design:

Step 1: Test the Wild-Type Reference Material

Test WT-W1 first to evaluate false-positive variant calls in a normal genomic background, assess analytical specificity, and establish background-noise thresholds for amplification or sequencing.

Step 2: Test the Heterozygous and Homozygous Variant Materials

Test HET-W2 and HOM-W3 to evaluate detection and discrimination of heterozygous and homozygous c.2333G>T genotypes and to assess analytical sensitivity and accuracy for the intended genotype calls.

Step 3: Perform Repeated Testing Across Conditions

Test all three reference materials on different dates, with different operators, and across relevant reagent lots to evaluate reproducibility and inter-lot variability of the complete workflow.

Step 4: Compare Results Across Platforms

Laboratories using both PCR/ddPCR and NGS can test the same ATP7B reference standard set to assess cross-platform genotype concordance. The resulting method-comparison and correlation data may support documentation prepared for assay registration or laboratory accreditation, subject to applicable regulatory and accreditation requirements.

Step 5: Incorporate the Materials into Routine Quality Control

After assay validation, the ATP7B reference standard set may be incorporated into routine quality control as positive and negative controls to monitor workflow performance over time, provided that the intended use and available stability data support this application.

VII. Summary

Well-characterized ATP7B reference standards representing relevant genotypes provide a foundation for evaluating a reproducible multi-platform Wilson disease testing workflow. A set containing wild-type, heterozygous, and homozygous human genomic DNA materials can be used to assess genotype accuracy, quantitative performance, reproducibility, and overall assay robustness.

CB-Gene ATP7B Reference Standards include wild-type, heterozygous, and homozygous human genomic DNA materials for the c.2333G>T variant. The genotypes are characterized using Sanger sequencing and digital PCR. The materials are intended to support Wilson disease assay development, analytical validation, cross-platform comparison, bioinformatics pipeline evaluation, and routine laboratory quality control, as applicable to the product's documented intended use.

For clinical molecular diagnostic laboratories, genetic disease research teams, and in vitro diagnostic developers, CB- Gene ATP7B Reference Standards provide standardized quality control materials in a human genomic DNA background for Wilson disease screening and molecular testing workflows.

Contact CB-Gene for detailed product information, instructions for use, and technical support for ATP7B reference standards used in multi-platform genetic test validation.